Travere Therapeutics, Inc.
TVTX · XNASCIK 1438533fmd_0T8VX4NSGNX44ATJB6QMXY9ZVCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Dec 01, 2009 to Sep 30, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 134 | 155 | 164 | 175 | 198 | 132 | 109 | 145 | 233 | 491 |
| Cost of revenue | 5 | 4 | 6 | 5 | 6 | 4 | 4 | 11 | 8 | 10 |
| Net interest income | 4 | 3 | 5 | – | – | – | – | – | – | – |
| Gross profit | 129 | 151 | 159 | 170 | 192 | 128 | 105 | 134 | 225 | 480 |
| Research and development | 71 | 78 | 124 | 141 | 132 | 201 | 8 | 245 | 217 | 206 |
| Selling, general and administrative | 92 | 101 | 104 | 129 | 136 | 126 | 198 | 266 | 264 | 337 |
| Total operating expenses | 192 | 209 | 244 | – | – | – | – | – | – | – |
| Compensation and benefits | – | – | – | – | – | – | – | – | – | – |
| Operating income | (58) | (54) | (80) | (137) | (176) | (199) | (320) | (388) | (324) | (63) |
| Interest expense | 5 | 4 | 10 | 19 | 19 | 20 | 11 | 11 | 11 | 11 |
| Interest and investment income | – | 3 | 5 | 10 | 5 | 2 | 6 | 22 | 18 | 13 |
| Other non-operating income (expense) | 1 | (5) | (22) | (9) | (13) | (17) | (11) | 12 | 3 | 14 |
| Income before taxes | (58) | (58) | (102) | (146) | (189) | (217) | (331) | (376) | (321) | (49) |
| Income tax expense | (10) | 1 | 1 | (0) | (19) | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | (48) | (60) | (103) | (146) | (169) | (217) | (331) | (376) | (321) | (50) |
| Net income | (48) | (60) | (103) | (146) | (169) | (180) | (278) | (111) | (322) | (26) |
| Net income to common shareholders | – | – | – | (146) | (169) | (180) | (278) | (111) | (322) | (26) |